Search

Your search keyword '"Onódi, Zsófia"' showing total 23 results
Start Over Author "Onódi, Zsófia"
23 results on '"Onódi, Zsófia"'

1. NASH triggers cardiometabolic HFpEF in aging mice

Author

Kucsera, Dániel, Ruppert, Mihály, Sayour, Nabil V., Tóth, Viktória E., Kovács, Tamás, Hegedűs, Zsombor I., Onódi, Zsófia, Fábián, Alexandra, Kovács, Attila, Radovits, Tamás, Merkely, Béla, Pacher, Pál, Ferdinandy, Péter, and Varga, Zoltán V.

Published
2024
Full Text
View/download PDF

2. Systematic transcriptomic and phenotypic characterization of human and murine cardiac myocyte cell lines and primary cardiomyocytes reveals serious limitations and low resemblances to adult cardiac phenotype

Author

Onódi, Zsófia, Visnovitz, Tamás, Kiss, Bernadett, Hambalkó, Szabolcs, Koncz, Anna, Ágg, Bence, Váradi, Barnabás, Tóth, Viktória É., Nagy, Regina N., Gergely, Tamás G., Gergő, Dorottya, Makkos, András, Pelyhe, Csilla, Varga, Nóra, Reé, Dóra, Apáti, Ágota, Leszek, Przemyslaw, Kovács, Tamás, Nagy, Nándor, Ferdinandy, Péter, Buzás, Edit I., Görbe, Anikó, Giricz, Zoltán, and Varga, Zoltán V.

Published
2022
Full Text
View/download PDF

4. Droplet Digital PCR Is a Novel Screening Method Identifying Potential Cardiac G-Protein-Coupled Receptors as Candidate Pharmacological Targets in a Rat Model of Pressure-Overload-Induced Cardiac Dysfunction

Author

Sayour, Nabil V., primary, Tóth, Viktória É., additional, Nagy, Regina N., additional, Vörös, Imre, additional, Gergely, Tamás G., additional, Onódi, Zsófia, additional, Nagy, Noémi, additional, Bödör, Csaba, additional, Váradi, Barnabás, additional, Ruppert, Mihály, additional, Radovits, Tamás, additional, Bleckwedel, Federico, additional, Zelarayán, Laura C., additional, Pacher, Pal, additional, Ágg, Bence, additional, Görbe, Anikó, additional, Ferdinandy, Péter, additional, and Varga, Zoltán V., additional

Published
2023
Full Text
View/download PDF

7. Characterization of immune checkpoint inhibitor‐induced cardiotoxicity reveals interleukin‐17A as a driver of cardiac dysfunction after anti‐PD‐1 treatment

Author

Gergely, Tamás G., primary, Kucsera, Dániel, additional, Tóth, Viktória E., additional, Kovács, Tamás, additional, Sayour, Nabil V., additional, Drobni, Zsófia D., additional, Ruppert, Mihály, additional, Petrovich, Balázs, additional, Ágg, Bence, additional, Onódi, Zsófia, additional, Fekete, Nóra, additional, Pállinger, Éva, additional, Buzás, Edit I., additional, Yousif, Laura I., additional, Meijers, Wouter C., additional, Radovits, Tamás, additional, Merkely, Béla, additional, Ferdinandy, Péter, additional, and Varga, Zoltán V., additional

Published
2022
Full Text
View/download PDF

8. Molecular determinants of immune checkpoint inhibitor-induced cardiac dysfunction: comparison of PD-1 inhibitor treated C57BL/6J and BALB/c mice

Author

Gergely, Tamás G., primary, Kucsera, Dániel, additional, Tóth, Viktória E., additional, Ruppert, Mihály, additional, Petrovich, Balázs, additional, Ágg, Bence, additional, Onódi, Zsófia, additional, Radovits, Tamás, additional, Merkely, Béla, additional, Ferdinandy, Péter, additional, and Varga, Zoltan, additional

Published
2022
Full Text
View/download PDF

11. PACAP-38 and PAC1 Receptor Alterations in Plasma and Cardiac Tissue Samples of Heart Failure Patients

Author

Szabó, Dóra, primary, Sárszegi, Zsolt, additional, Polgár, Beáta, additional, Sághy, Éva, additional, Reglődi, Dóra, additional, Tóth, Tünde, additional, Onódi, Zsófia, additional, Leszek, Przemyslaw, additional, Varga, Zoltán V., additional, Helyes, Zsuzsanna, additional, Kemény, Ágnes, additional, Ferdinandy, Péter, additional, and Tamás, Andrea, additional

Published
2022
Full Text
View/download PDF

12. Drug repurposing for cardiovascular diseases: New targets and indications for probenecid.

Author

Onódi, Zsófia, Koch, Sheryl, Rubinstein, Jack, Ferdinandy, Péter, and Varga, Zoltán V.

Subjects
*DRUG repositioning, *CARDIOVASCULAR diseases, *CARDIOVASCULAR agents, *DRUG target, *HEART diseases, *DEMAND forecasting
Abstract

The available pharmacological options in the management of cardiovascular diseases such as ischaemic heart disease and subsequent heart failure are effective in slowing the progression of this condition. However, the long‐term prognosis is still poor, raising the demand for new therapeutic strategies. Drug repurposing is a time‐ and cost‐effective drug development strategy that offers approved and abandoned drugs a new chance for new indications. Recently, drugs used for the management of gout‐related inflammation such as canakinumab or colchicine have been considered for drug repurposing in cardiovascular indications. The old uricosuric drug, probenecid, has been identified as a novel therapeutic option in the management of specific cardiac diseases as well. Probenecid can modulate myocardial contractility and vascular tone and exerts anti‐inflammatory properties. The mechanisms behind these beneficial effects might be related inhibition of inflammasomes, and to modulation purinergic–pannexin‐1 signalling and TRPV2 channels, which are recently identified molecular targets of probenecid. In this review, we provide an overview on repurposing probenecid for ischaemic heart disease and subsequent heart failure by summarizing the related experimental and clinical data and propose its potential repurposing to treat cardiovascular diseases. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

13. Characterization of immune checkpoint inhibitor‐induced cardiotoxicity reveals interleukin‐17A as a driver of cardiac dysfunction after anti‐PD‐1 treatment.

Author

Gergely, Tamás G., Kucsera, Dániel, Tóth, Viktória E., Kovács, Tamás, Sayour, Nabil V., Drobni, Zsófia D., Ruppert, Mihály, Petrovich, Balázs, Ágg, Bence, Onódi, Zsófia, Fekete, Nóra, Pállinger, Éva, Buzás, Edit I., Yousif, Laura I., Meijers, Wouter C., Radovits, Tamás, Merkely, Béla, Ferdinandy, Péter, and Varga, Zoltán V.

Subjects
HEART diseases, IMMUNE checkpoint proteins, CARDIOTOXICITY, MONOCLONAL antibodies, MYOCARDIAL reperfusion, IMMUNE checkpoint inhibitors, VENTRICULAR dysfunction
Abstract

Background and Purpose: Immune checkpoint inhibitors (ICI), such as anti‐PD‐1 monoclonal antibodies, have revolutionized cancer therapy by enhancing the cytotoxic effects of T‐cells against tumours. However, enhanced T‐cell activity also may cause myocarditis and cardiotoxicity. Our understanding of the mechanisms of ICI‐induced cardiotoxicity is limited. Here, we aimed to investigate the effect of PD‐1 inhibition on cardiac function and explore the molecular mechanisms of ICI‐induced cardiotoxicity. Experimental Approach: C57BL6/J and BALB/c mice were treated with isotype control or anti‐PD‐1 antibody. Echocardiography was used to assess cardiac function. Cardiac transcriptomic changes were investigated by bulk RNA sequencing. Inflammatory changes were assessed by qRT‐PCR and immunohistochemistry in heart, thymus, and spleen of the animals. In follow‐up experiments, anti‐CD4 and anti‐IL‐17A antibodies were used along with PD‐1 blockade in C57BL/6J mice. Key Results: Anti‐PD‐1 treatment led to cardiac dysfunction and left ventricular dilation in C57BL/6J mice, with increased nitrosative stress. Only mild inflammation was observed in the heart. However, PD‐1 inhibition resulted in enhanced thymic inflammatory signalling, where Il17a increased most prominently. In BALB/c mice, cardiac dysfunction was not evident, and thymic inflammatory activation was more balanced. Inhibition of IL‐17A prevented anti‐PD‐1‐induced cardiac dysfunction in C57BL6/J mice. Comparing myocardial transcriptomic changes in C57BL/6J and BALB/c mice, differentially regulated genes (Dmd, Ass1, Chrm2, Nfkbia, Stat3, Gsk3b, Cxcl9, Fxyd2, and Ldb3) were revealed, related to cardiac structure, signalling, and inflammation. Conclusions: PD‐1 blockade induces cardiac dysfunction in mice with increased IL‐17 signalling in the thymus. Pharmacological inhibition of IL‐17A treatment prevents ICI‐induced cardiac dysfunction. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

14. Somatostatin and Its Receptors in Myocardial Ischemia/Reperfusion Injury and Cardioprotection

Author

Vörös, Imre, primary, Sághy, Éva, additional, Pohóczky, Krisztina, additional, Makkos, András, additional, Onódi, Zsófia, additional, Brenner, Gábor B., additional, Baranyai, Tamás, additional, Ágg, Bence, additional, Váradi, Barnabás, additional, Kemény, Ágnes, additional, Leszek, Przemyslaw, additional, Görbe, Anikó, additional, Varga, Zoltán V., additional, Giricz, Zoltán, additional, Schulz, Rainer, additional, Helyes, Zsuzsanna, additional, and Ferdinandy, Péter, additional

Published
2021
Full Text
View/download PDF

15. AIM2-driven inflammasome activation in heart failure

Author

Onódi, Zsófia, primary, Ruppert, Mihály, additional, Kucsera, Dániel, additional, Sayour, Alex Ali, additional, Tóth, Viktória E, additional, Koncsos, Gábor, additional, Novák, Julianna, additional, Brenner, Gábor B, additional, Makkos, András, additional, Baranyai, Tamás, additional, Giricz, Zoltán, additional, Görbe, Anikó, additional, Leszek, Przemyslaw, additional, Gyöngyösi, Mariann, additional, Horváth, Iván G, additional, Schulz, Rainer, additional, Merkely, Béla, additional, Ferdinandy, Péter, additional, Radovits, Tamás, additional, and Varga, Zoltán V, additional

Published
2021
Full Text
View/download PDF

16. Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Author

Brenner, Gábor B, primary, Giricz, Zoltán, primary, Garamvölgyi, Rita, primary, Makkos, András, primary, Onódi, Zsófia, primary, Sayour, Nabil V, primary, Gergely, Tamás G, primary, Baranyai, Tamás, primary, Petneházy, Örs, primary, Kőrösi, Dénes, primary, Szabó, Gergő P., primary, Vago, Hajnalka, primary, Dohy, Zsófia, primary, Czimbalmos, Csilla, primary, Merkely, Béla, primary, Boldin-Adamsky, Swetlana, primary, Feinstein, Elena, primary, Horváth, Iván G, primary, and Ferdinandy, Péter, primary

Published
2021
Full Text
View/download PDF

18. Hidden Cardiotoxicity of Rofecoxib Can be Revealed in Experimental Models of Ischemia/Reperfusion

Author

Brenner, Gábor B., primary, Makkos, András, additional, Nagy, Csilla Terézia, additional, Onódi, Zsófia, additional, Sayour, Nabil V., additional, Gergely, Tamás G., additional, Kiss, Bernadett, additional, Görbe, Anikó, additional, Sághy, Éva, additional, Zádori, Zoltán S., additional, Lázár, Bernadette, additional, Baranyai, Tamás, additional, Varga, Richárd S., additional, Husti, Zoltán, additional, Varró, András, additional, Tóthfalusi, László, additional, Schulz, Rainer, additional, Baczkó, István, additional, Giricz, Zoltán, additional, and Ferdinandy, Péter, additional

Published
2020
Full Text
View/download PDF

19. Isolation of High-Purity Extracellular Vesicles by the Combination of Iodixanol Density Gradient Ultracentrifugation and Bind-Elute Chromatography From Blood Plasma

Author

Onódi, Zsófia, primary, Pelyhe, Csilla, additional, Terézia Nagy, Csilla, additional, Brenner, Gábor B., additional, Almási, Laura, additional, Kittel, Ágnes, additional, Manček-Keber, Mateja, additional, Ferdinandy, Péter, additional, Buzás, Edit I., additional, and Giricz, Zoltán, additional

Published
2018
Full Text
View/download PDF

20. Selegiline reduces adiposity induced by high-fat, high-sucrose diet in male rats

Author

Nagy, Csilla Terézia, primary, Koncsos, Gábor, additional, Varga, Zoltán V, additional, Baranyai, Tamás, additional, Tuza, Sebestyén, additional, Kassai, Ferenc, additional, Ernyey, Aliz Judit, additional, Gyertyán, István, additional, Király, Kornél, additional, Oláh, Attila, additional, Radovits, Tamás, additional, Merkely, Béla, additional, Bukosza, Nóra, additional, Szénási, Gábor, additional, Hamar, Péter, additional, Mathé, Domokos, additional, Szigeti, Krisztián, additional, Pelyhe, Csilla, additional, Jelemenský, Marek, additional, Onódi, Zsófia, additional, Helyes, Zsuzsanna, additional, Schulz, Rainer, additional, Giricz, Zoltán, additional, and Ferdinandy, Péter, additional

Published
2018
Full Text
View/download PDF

21. Isolation of Exosomes from Blood Plasma: Qualitative and Quantitative Comparison of Ultracentrifugation and Size Exclusion Chromatography Methods

Author

Baranyai, Tamás, primary, Herczeg, Kata, additional, Onódi, Zsófia, additional, Voszka, István, additional, Módos, Károly, additional, Marton, Nikolett, additional, Nagy, György, additional, Mäger, Imre, additional, Wood, Matthew J., additional, El Andaloussi, Samir, additional, Pálinkás, Zoltán, additional, Kumar, Vikas, additional, Nagy, Péter, additional, Kittel, Ágnes, additional, Buzás, Edit Irén, additional, Ferdinandy, Péter, additional, and Giricz, Zoltán, additional

Published
2015
Full Text
View/download PDF

23. CardiLect: A combined cross-species lectin histochemistry protocol for the automated analysis of cardiac remodelling.

Author

Gergely TG, Kovács T, Kovács A, Tóth VE, Sayour NV, Mórotz GM, Kovácsházi C, Brenner GB, Onódi Z, Enyedi B, Máthé D, Leszek P, Giricz Z, Ferdinandy P, and Varga ZV

Abstract

Background: Cardiac remodelling, a crucial aspect of heart failure, is commonly investigated in preclinical models by quantifying cardiomyocyte cross-sectional area (CSA) and microvascular density (MVD) via histological methods, such as immunohistochemistry. To achieve this, optimized protocols are needed, and the species specificity is dependent on the antibody used. Lectin histochemistry offers several advantages compared to antibody-based immunohistochemistry, including as cost-effectiveness and cross-species applicability. Direct comparisons between the two methods are lacking from the literature., Methods and Results: In this study, we compared antibody- and lectin-based methods for the histological assessment of cardiomyocyte CSA (with the use of anti-laminin and wheat germ agglutinin [WGA]) and microvascular density (utilizing anti-CD31 and isolectin B4 [ILB4]) using different embedding and antigen/carbohydrate retrieval techniques. Here, we describe a detailed, easy-to-use combined lectin histochemistry protocol (WGA and ILB4, 'CardiLect' protocol) for the histological assessment of cardiac remodelling. The lectin-based approach has been evaluated on a cross-species basis, and its efficacy has been demonstrated in zebrafish, rodents, large animals and human samples. We provide an ImageJ script ('CardiLect Analyser') for automated image analysis, validated in a preclinical heart failure model by correlating histological parameters with echocardiographic findings. CSA showed a significant positive correlation with left ventricular (LV) mass (P = 0.0098, r S  = 0.7545) and significant negative correlation with markers of systolic function, such as ejection fraction (EF) (P = 0.0402, r S  = -0.6364). Microvascular density showed significant negative correlation with LV mass (P = 0.0055, r S  = -0.7622) and significant positive correlation with EF (P = 0.0106, r S  = 0.7203)., Conclusions: The described combined lectin histochemistry protocol with the provided ImageJ script is an easy-to-use, cost-effective, cross-species approach for the histological assessment of cardiac remodelling., (© 2024 The Author(s). ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results